PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Net Income: MAD59.9 Mil (TTM As of Dec. 2025)


CAS:PRO PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
87 GF Score
Price MAD1,349.00
GF Value MAD1,331.32
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Income?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 87 Net Income is MAD59.9 Mil as of Dec. 2025. GuruFocus rates CAS:PRO with a GF Score™ of 87/100 and a GF Value™ of MAD1,331.32 (Fairly Valued). The stock has 6 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income for the six months ended in Dec. 2025 was MAD33.7 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was MAD59.9 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was MAD33.66.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM  (CAS:PRO) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Income Related Terms


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Income Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Income Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.97 75.28 56.90 55.16 59.92

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.50 24.22 30.94 26.25 33.66
CAS:PRO
87GF Score
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income for the fiscal year that ended in Dec. 2025 is calculated as

Net Income(A: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=98.376+-38.461+0+-7.105427357601E-15
=59.9

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income for the quarter that ended in Dec. 2025 is calculated as

Net Income(Q: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=50.953+-17.29+0+-0.0010000000000048
=33.7

Net Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MAD59.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of MAD59.9 Mil mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Net Income of MAD59.9 Mil as of Dec. 2025. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Net Income is MAD59.9 Mil. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income compare to ZTS and UTHR?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Income of MAD59.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Drug Manufacturers company?
A good Net Income depends on the Drug Manufacturers industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Net Income is MAD59.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,331.32, compared to a current price of MAD1,349.00 — trading 1.3% above its estimated fair value. The current Net Income is MAD59.9 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Net Income is MAD59.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued. The current stock price of MAD1,349.00 is trading 1.3% above its estimated GF Value™ of MAD1,331.32. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

  • Net Income: MAD59.9 Mil
  • GF Value™: MAD1,331.32 vs. price of MAD1,349.00 (1.3% above fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
87GF Score

Get the complete analysis for CAS:PRO

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,349.00
Price
MAD1,331.32
GF Value